Novo Phase IIb stroke data

NVO said in a double-blind Phase IIb trial in 400 patients with intracerebral hemorrhage (ICH), treatment with its NovoSeven significantly reduced hematoma growth compared to placebo, the primary endpoint. Patients in the international trial treated with NovoSeven also had improved neurological and functional outcomes. There was a non-significant increase in thromboembolic events in the NovoSeven group. ...